珈凯生物
(920165)
| 流通市值：0.00万 | | | 总市值：0.00万 |
| 流通股本：0.00万 | | | 总股本：0.00万 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 74,949,661.97 | 262,659,452.34 | 194,811,084.95 | 122,118,506.58 |
| 营业总成本 | 52,787,232.97 | 191,607,475.3 | 142,492,352.08 | 92,073,796.35 |
| 其他经营收益 | | | | |
| 营业利润 | 21,935,217.63 | 76,695,512.72 | 55,162,585.71 | 33,472,644.45 |
| 利润总额 | 21,879,718.79 | 76,500,749.4 | 54,987,073.21 | 33,400,001.92 |
| 净利润 | 19,303,319.95 | 66,269,289.72 | 47,301,550.79 | 29,019,222.89 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 19,303,319.95 | 66,269,289.72 | 47,301,550.79 | 29,019,222.89 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 217,280,907 | 192,188,708.5 | 171,903,377.01 | 146,422,068.89 |
| 非流动资产: | | | | |
| 非流动资产合计 | 295,967,810.23 | 299,951,210.09 | 304,846,588.36 | 308,308,328.21 |
| 资产总计 | 513,248,717.23 | 492,139,918.59 | 476,749,965.37 | 454,730,397.1 |
| 流动负债: | | | | |
| 流动负债合计 | 36,917,944.65 | 36,285,362.75 | 39,762,513.58 | 36,765,778.59 |
| 非流动负债: | | | | |
| 非流动负债合计 | 14,237,806.32 | 13,812,932.11 | 14,661,589.57 | 14,669,106.77 |
| 负债合计 | 51,155,750.97 | 50,098,294.86 | 54,424,103.15 | 51,434,885.36 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 462,092,966.26 | 442,041,623.73 | 422,325,862.22 | 403,295,511.74 |
| 股东权益合计 | 462,092,966.26 | 442,041,623.73 | 422,325,862.22 | 403,295,511.74 |
| 负债和股东权益合计 | 513,248,717.23 | 492,139,918.59 | 476,749,965.37 | 454,730,397.1 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 78,678,657.87 | 301,109,326.86 | 215,610,900.59 | 147,728,227.78 |
| 经营活动现金流出小计 | 63,254,047.62 | 209,580,089.1 | 160,374,256.06 | 105,888,340.99 |
| 经营活动产生的现金流量净额 | 15,424,610.25 | 91,529,237.76 | 55,236,644.53 | 41,839,886.79 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 190,349,325.69 | 378,564,284.9 | 253,395,240.21 | 168,220,162.97 |
| 投资活动现金流出小计 | 163,639,730.35 | 452,937,617.05 | 295,890,408.15 | 177,983,881.81 |
| 投资活动产生的现金流量净额 | 26,709,595.34 | -74,373,332.15 | -42,495,167.94 | -9,763,718.84 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | 67,475.24 | - |
| 筹资活动现金流出小计 | 678,279 | 36,174,671.99 | 36,253,080.32 | 33,395,224.77 |
| 筹资活动产生的现金流量净额 | -678,279 | -36,174,671.99 | -36,185,605.08 | -33,395,224.77 |
| 汇率变动对现金及现金等价物的影响 | -228,122.24 | 83,978.91 | 133,751.73 | 286,469.55 |
| 现金及现金等价物净增加额 | 41,227,804.35 | -18,934,787.47 | -23,310,376.76 | -1,032,587.27 |
| 期末现金及现金等价物余额 | 100,224,320.18 | 58,996,515.83 | 54,620,926.54 | 76,898,716.03 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -18,934,787.47 | - | -1,032,587.27 |